OBJECTIVE: Some patients with rheumatoid arthritis (RA) exhibit lymphocyte aggregates in the synovium. This study was undertaken to address whether the presence of lymphocyte aggregates before treatment could serve as a biomarker for the clinical response to tumor necrosis factor (TNF) blockade, and to confirm whether the aggregation of synovial lymphocytes is reversible after anti-TNF treatment. METHODS: Synovial tissue biopsy samples were obtained from 97 patients with active RA before the initiation of infliximab treatment. Lymphocyte aggregates in the synovial tissue were counted and also graded for size. Logistic regression analysis was performed to identify whether the presence of lymphocyte aggregates could be a predictor of the clinical response at week 16. Furthermore, the effects of TNF blockade on lymphocyte aggregates were compared between patients with RA and patients with psoriatic arthritis (PsA). RESULTS: Fifty-seven percent of RA synovial tissue samples contained lymphocyte aggregates, and 32% of the patients had large aggregates. Aggregates were found in 67% of clinical responders compared with 38% of nonresponders. The presence of aggregates at baseline was a highly significant predictor of the clinical response to anti-TNF treatment (R(2) = 0.10, P = 0.008). Positivity for lymphocyte aggregates increased the power to predict the clinical response (R(2) = 0.29), when analyzed in a prediction model that included baseline disease activity evaluated by the Disease Activity Score in 28 joints, anti-cyclic citrullinated peptide antibody positivity, and synovial TNFalpha expression. There was a reduction in lymphocyte aggregates after anti-TNF antibody therapy in both RA and PsA. CONCLUSION: RA patients with synovial lymphocyte aggregates have, on average, a better response to infliximab treatment than those with only diffuse leukocyte infiltration. Moreover, the aggregation of synovial lymphocytes is reversible after anti-TNF antibody treatment.
OBJECTIVE: Some patients with rheumatoid arthritis (RA) exhibit lymphocyte aggregates in the synovium. This study was undertaken to address whether the presence of lymphocyte aggregates before treatment could serve as a biomarker for the clinical response to tumor necrosis factor (TNF) blockade, and to confirm whether the aggregation of synovial lymphocytes is reversible after anti-TNF treatment. METHODS: Synovial tissue biopsy samples were obtained from 97 patients with active RA before the initiation of infliximab treatment. Lymphocyte aggregates in the synovial tissue were counted and also graded for size. Logistic regression analysis was performed to identify whether the presence of lymphocyte aggregates could be a predictor of the clinical response at week 16. Furthermore, the effects of TNF blockade on lymphocyte aggregates were compared between patients with RA and patients with psoriatic arthritis (PsA). RESULTS: Fifty-seven percent of RA synovial tissue samples contained lymphocyte aggregates, and 32% of the patients had large aggregates. Aggregates were found in 67% of clinical responders compared with 38% of nonresponders. The presence of aggregates at baseline was a highly significant predictor of the clinical response to anti-TNF treatment (R(2) = 0.10, P = 0.008). Positivity for lymphocyte aggregates increased the power to predict the clinical response (R(2) = 0.29), when analyzed in a prediction model that included baseline disease activity evaluated by the Disease Activity Score in 28 joints, anti-cyclic citrullinated peptide antibody positivity, and synovial TNFalpha expression. There was a reduction in lymphocyte aggregates after anti-TNF antibody therapy in both RA and PsA. CONCLUSION:RApatients with synovial lymphocyte aggregates have, on average, a better response to infliximab treatment than those with only diffuse leukocyte infiltration. Moreover, the aggregation of synovial lymphocytes is reversible after anti-TNF antibody treatment.
Authors: Carl Orr; Elsa Vieira-Sousa; David L Boyle; Maya H Buch; Christopher D Buckley; Juan D Cañete; Anca I Catrina; Ernest H S Choy; Paul Emery; Ursula Fearon; Andrew Filer; Danielle Gerlag; Frances Humby; John D Isaacs; Søren A Just; Bernard R Lauwerys; Benoit Le Goff; Antonio Manzo; Trudy McGarry; Iain B McInnes; Aurélie Najm; Constantino Pitzalis; Arthur Pratt; Malcolm Smith; Paul P Tak; Rogier Thurlings; João E Fonseca; Douglas J Veale; Sander W Tas Journal: Nat Rev Rheumatol Date: 2017-07-13 Impact factor: 20.543
Authors: Liisa M Virkki; Heikki Valleala; Yuya Takakubo; Jorma Vuotila; Heikki Relas; Riitta Komulainen; Riitta Koivuniemi; Urpo Yli-Kerttula; Markku Mali; Susanna Sihvonen; Maija-Liisa Krogerus; Eero Jukka; Satu Nyrhinen; Yrjö T Konttinen; Dan C Nordström Journal: Clin Rheumatol Date: 2011-06-07 Impact factor: 2.980
Authors: Dana E Orange; Phaedra Agius; Edward F DiCarlo; Nicolas Robine; Heather Geiger; Jackie Szymonifka; Michael McNamara; Ryan Cummings; Kathleen M Andersen; Serene Mirza; Mark Figgie; Lionel B Ivashkiv; Alessandra B Pernis; Caroline S Jiang; Mayu O Frank; Robert B Darnell; Nithya Lingampali; William H Robinson; Ellen Gravallese; Vivian P Bykerk; Susan M Goodman; Laura T Donlin Journal: Arthritis Rheumatol Date: 2018-04-02 Impact factor: 10.995
Authors: Maša Umiċeviċ Mirkov; Jing Cui; Sita H Vermeulen; Eli A Stahl; Erik J M Toonen; Remco R Makkinje; Annette T Lee; Tom W J Huizinga; Renee Allaart; Anne Barton; Xavier Mariette; Corinne Richard Miceli; Lindsey A Criswell; Paul P Tak; Niek de Vries; Saedis Saevarsdottir; Leonid Padyukov; S Louis Bridges; Dirk-Jan van Schaardenburg; Tim L Jansen; Ellen A J Dutmer; Mart A F J van de Laar; Pilar Barrera; Timothy R D J Radstake; Piet L C M van Riel; Hans Scheffer; Barbara Franke; Han G Brunner; Robert M Plenge; Peter K Gregersen; Henk-Jan Guchelaar; Marieke J H Coenen Journal: Ann Rheum Dis Date: 2012-12-11 Impact factor: 19.103
Authors: Johan Lindberg; Carla A Wijbrandts; Lisa G van Baarsen; Gustavo Nader; Lars Klareskog; Anca Catrina; Rogier Thurlings; Margriet Vervoordeldonk; Joakim Lundeberg; Paul P Tak Journal: PLoS One Date: 2010-06-25 Impact factor: 3.240